Literature DB >> 9400599

Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid.

H Goto1, R C Bethell, Y Kawaoka.   

Abstract

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid (4-guanidino-Neu5Ac2en) specifically inhibits the influenza virus neuraminidase (NA) through interaction of the guanidino group with conserved Glu 119 and Glu 227 residues in the substrate binding pocket of the enzyme. To understand the mechanism by which influenza viruses become resistant to 4-guanidino-Neu5Ac2en, we investigated mutations at amino acid residues 119 and 227 in the influenza virus NA for their effects on this compound and on NA activity. The NA gene was cloned from the NWS-G70c virus, and mutations were introduced at the codon for amino acid residue 119 or 227. All of the 13 mutants containing a change at residue 119 were transported to the cell surface, although their expression levels ranged from 68.2 to 91.3% of wild type. Mutant NAs that retained at least 20% of the wild-type enzymatic activity were tested for their sensitivity to 4-guanidino-Neu5Ac2en and found to be sevenfold less sensitive to this compound than was the wild-type NA. By contrast, only 6 of 13 mutants defined by modifications at residue 227 were transported to the cell surface, and those NAs lacked substantial enzymatic activity (9% of wild type, at most). These results suggest that only a limited number of resistant viruses arise through mutations at Glu 119 and Glu 227 under selective pressure from 4-guanidino-Neu5Ac2en and that the development of compounds which interact with 227 Glu more strongly than does 4-guanidino-Neu5Ac2en may reduce the likelihood of drug-resistant viruses still further.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9400599     DOI: 10.1006/viro.1997.8810

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses.

Authors:  Hui-Ling Yen; Erich Hoffmann; Garry Taylor; Christoph Scholtissek; Arnold S Monto; Robert G Webster; Elena A Govorkova
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  An adenovirus vector-mediated reverse genetics system for influenza A virus generation.

Authors:  Makoto Ozawa; Hideo Goto; Taisuke Horimoto; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

3.  Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir.

Authors:  Michael Z Wang; Chun Y Tai; Dirk B Mendel
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

4.  Generation of influenza A viruses entirely from cloned cDNAs.

Authors:  G Neumann; T Watanabe; H Ito; S Watanabe; H Goto; P Gao; M Hughes; D R Perez; R Donis; E Hoffmann; G Hobom; Y Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 5.  Zanamivir: a review of its use in influenza.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

Review 6.  Pandemic threat posed by avian influenza A viruses.

Authors:  T Horimoto; Y Kawaoka
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

7.  Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies.

Authors:  J M Barnett; A Cadman; D Gor; M Dempsey; M Walters; A Candlin; M Tisdale; P J Morley; I J Owens; R J Fenton; A P Lewis; E C Claas; G F Rimmelzwaan; R De Groot; A D Osterhaus
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

8.  A generic system for the expression and purification of soluble and stable influenza neuraminidase.

Authors:  Peter M Schmidt; Rebecca M Attwood; Peter G Mohr; Susan A Barrett; Jennifer L McKimm-Breschkin
Journal:  PLoS One       Date:  2011-02-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.